The latest research progress and prospects of pazopanib combined with immunotherapy

Pazopanib is a multi-target tyrosine kinase inhibitor that mainly exerts anti-tumor and anti-angiogenic effects by inhibiting VEGFR, PDGFR, c-KIT and other targets. Pazopanib is currently approved for the treatment of advanced renal cell carcinoma (RCC) and soft tissue sarcoma (STS). In recent years, researchers have explored the combination treatment strategy of pazopanib and immune checkpoint inhibitors (such as PD-1/PD-L1inhibitors), aiming to improve the anti-tumor efficacy through synergy. This article will review the latest research progress of pazopanib combined with immunotherapy and look forward to its future clinical application prospects.

1. Research progress on the combination of pazopanib and immunotherapy

In renal cell carcinoma (RCC), pazopanib in combination with immune checkpoint inhibitors has been evaluated in multiple clinical trials. For example, a phase I/II study evaluated the safety and preliminary efficacy of pazopanib plus pembrolizumab in patients with advanced RCC. The results showed that this combination regimen achieved good efficacy in some patients and was tolerable.

In soft tissue sarcoma (STS), the combination treatment of pazopanib and immune checkpoint inhibitors is also being explored. One study evaluated the combination of pazopanib and durvalumab in patients with advanced STS. The results show that this combination regimen shows promising efficacy in some patients, and the adverse reactions are controllable.

2. Mechanistic basis of combined therapy

Pazopanib inhibits tumor-related angiogenesis and reduces immunosuppressive factors in the tumor microenvironment, such asVEGF, thereby potentially enhancing the infiltration and activity of immune cells. Immune checkpoint inhibitors enhance the anti-tumor immune response by releasing the inhibition of T cells. Therefore, the combination treatment of pazopanib and immune checkpoint inhibitors may synergistically improve the anti-tumor effect through dual mechanisms.

3. Challenges and prospects in clinical research

Although the combination of pazopanib and immunotherapy has shown good efficacy in some patients, it still faces some challenges. First, combination therapy may increase the incidence of adverse reactions and needs to be carefully evaluated in clinical practice. Secondly, how to select appropriate patient groups and how to monitor and manage possible immune-related adverse events are the focus of current research. Future studies are needed to further clarify the optimal regimen of combination therapy, treatment duration, and patient selection criteria.

4. Future research directions

Future research can be explored from the following directions:

1.Biomarker screening: By identifying biomarkers that predict response to combination therapy, the patient groups most likely to benefit will be screened.

2. Optimization of combination treatment regimens: Evaluate different doses, dosing sequences, and combination regimens to determine the best treatment strategy.

3.Management of immune-related adverse events: Establish effective monitoring and management strategies to reduce the occurrence of immune-related adverse events and improve patient tolerance.

4.Exploration of other tumor types: In addition to RCC and STS, the application of pazopanib combined with immunotherapy in other tumor types also deserves further study.

The combination of pazopanib and immunotherapy has shown potential efficacy in patients with advanced RCC and STS, providing a new treatment option. However, further clinical research is still needed to optimize treatment options, screen appropriate patient groups, and effectively manage possible adverse effects. With the deepening of research, pazopanib combined with immunotherapy is expected to play a role in more tumor types and bring better treatment prospects to patients.

Reference materials:https://www.drugs.com/